Lineage specific extracellular vesicle-associated protein biomarkers for the early detection of high grade serous ovarian cancer

• Published in: Scientific reports Vol. 13; no. 1; p. 18341
• Main Authors: Trinidad, Camille V., Pathak, Harsh B., Cheng, Shibo, Tzeng, Shin-Cheng, Madan, Rashna, Sardiu, Mihaela E., Bantis, Leonidas E., Deighan, Clayton, Jewell, Andrea, Rayamajhi, Sagar, Zeng, Yong, Godwin, Andrew K.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 26.10.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/67; 631/67/1857; 692/4028/67; 692/53; Antigens; Biomarkers; Biomarkers, Tumor - metabolism; Case-Control Studies; Early Detection of Cancer; Explants; Extracellular Vesicles - metabolism; Female; Folate Receptor 1; Humanities and Social Sciences; Humans; Mass spectrometry; Mass spectroscopy; Microfluidics; multidisciplinary; Ovarian cancer; Ovarian carcinoma; Ovarian Neoplasms - pathology; Proteins; Proteomes; Regression analysis; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-44050-5

High grade serous ovarian carcinoma (HGSOC) accounts for ~ 70% of ovarian cancer cases. Non-invasive, highly specific blood-based tests for pre-symptomatic screening in women are crucial to reducing the mortality associated with this disease. Since most HGSOCs typically arise from the fallopian tubes (FT), our biomarker search focused on proteins found on the surface of extracellular vesicles (EVs) released by both FT and HGSOC tissue explants and representative cell lines. Using mass spectrometry, 985 EV proteins (exo-proteins) were identified that comprised the FT/HGSOC EV core proteome. Transmembrane exo-proteins were prioritized because these could serve as antigens for capture and/or detection. With a nano-engineered microfluidic platform, six newly discovered exo-proteins (ACSL4, IGSF8, ITGA2, ITGA5, ITGB3, MYOF) plus a known HGSOC associated protein, FOLR1 exhibited classification performance ranging from 85 to 98% in a case–control study using plasma samples representative of early (including stage IA/B) and late stage (stage III) HGSOCs. Furthermore, by a linear combination of IGSF8 and ITGA5 based on logistic regression analysis, we achieved a sensitivity of 80% with 99.8% specificity and a positive predictive value of 13.8%. Importantly, these exo-proteins also can accurately discriminate between ovarian and 12 types of cancers commonly diagnosed in women. Our studies demonstrate that these lineage-associated exo-biomarkers can detect ovarian cancer with high specificity and sensitivity early and potentially while localized to the FT when patient outcomes are more favorable.